Alzheimer's Disease Therapeutics
•32 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (32)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Kisunla and Alzheimer's therapeutic program anchor neuroscience focus.
|
$816.66B |
$863.11
+2.20%
|
|
BMY
Bristol-Myers Squibb Company
Cobenfy's Alzheimer's- and cognition-related readouts justify Alzheimer's Disease Therapeutics as a tag.
|
$93.77B |
$46.11
+1.07%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Pipeline asset mivelsiran targets Alzheimer's disease, aligning with Alzheimer's Disease Therapeutics.
|
$59.78B |
$456.03
+1.44%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$22.62B |
$154.27
+3.11%
|
|
AXSM
Axsome Therapeutics, Inc.
AXS-05 is being developed for Alzheimer's Disease agitation, aligning with Alzheimer's Disease Therapeutics as a focus.
|
$6.65B |
$135.04
+1.42%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
ARO-MAPT targets Tau for Alzheimer's disease, fitting Alzheimer's Disease Therapeutics.
|
$5.85B |
$42.40
+0.20%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACP-204 targets Alzheimer's disease psychosis, positioning ACADIA within Alzheimer's disease therapeutics.
|
$3.80B |
$22.70
-0.20%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Positive Alzheimer's Disease biomarker data (p-tau217) from BROADWAY suggests potential Alzheimer's disease therapeutic applications.
|
$3.51B |
$37.92
-2.07%
|
|
AVXL
Anavex Life Sciences Corp.
Alzheimer's disease therapeutics tag applies to blarcamesine and the EMA Alzheimer's program.
|
$680.41M |
$7.96
-0.87%
|
|
PRTA
Prothena Corporation plc
The pipeline and lead programs focus on Alzheimer's disease therapeutics (e.g., PRX012) and related neurodegenerative targets.
|
$578.64M |
$10.73
+2.43%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
NMRA-511 targets Alzheimer's disease agitation, fitting Alzheimer's Disease Therapeutics.
|
$488.48M |
$3.00
+2.39%
|
|
VIGL
Vigil Neuroscience, Inc.
The company is pursuing therapies for Alzheimer's disease with TREM2 agonism, aligning with Alzheimer's Disease Therapeutics.
|
$375.71M |
$8.05
|
|
ACIU
AC Immune S.A.
Alzheimer's Disease Therapeutics – the company focuses on active immunotherapies and diagnostic assets for Alzheimer's disease.
|
$337.46M |
$3.38
|
|
VYGR
Voyager Therapeutics, Inc.
Alzheimer's disease-focused tau/APOE programs place Voyager in Alzheimer's Disease Therapeutics.
|
$258.42M |
$4.67
+3.32%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA is advancing Alzheimer's Disease therapeutics with evidence of neuroinflammation reduction and Phase 2 trials, fitting Alzheimer's Disease Therapeutics.
|
$197.93M |
$1.90
+3.26%
|
|
ALEC
Alector, Inc.
AL101 is targeted for Alzheimer's disease, placing it in Alzheimer's disease therapeutics.
|
$146.99M |
$1.48
-2.96%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is developed as an Alzheimer's disease therapeutic.
|
$133.87M |
$2.19
-1.13%
|
|
CGTX
Cognition Therapeutics, Inc.
The lead candidate is being developed for Alzheimer’s disease with Phase 2 data supporting disease-modifying potential in AD.
|
$110.97M |
$1.79
+8.79%
|
|
COYA
Coya Therapeutics, Inc.
COYA's LD IL-2-based assets and early AD biomarker data support an Alzheimer's disease therapeutics angle.
|
$105.70M |
$6.29
+2.78%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$99.16M |
$6.11
-1.13%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$48.65M |
$1.82
+5.49%
|
|
JUNS
Jupiter Neurosciences, Inc.
Alzheimer's Disease Therapeutics: Pipeline consideration includes cognitive impairment/early Alzheimer's indications.
|
$47.34M |
$1.42
+2.90%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$40.92M |
$2.10
+0.72%
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$33.16M |
$0.40
-0.60%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
MIRA-55's focus on cognitive decline aligns with Alzheimer's Disease Therapeutics.
|
$28.26M |
$1.69
+2.12%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-ALZ targets Alzheimer's disease, supporting Alzheimer's disease therapeutics as a focus area.
|
$18.76M |
$1.41
+3.68%
|
|
PMN
ProMIS Neurosciences, Inc.
Alzheimer's Disease Therapeutics captures PMN's primary disease focus and lead program.
|
$13.57M |
$0.42
+0.29%
|
|
LGVN
Longeveron Inc.
Alzheimer's Disease Therapeutics is a stated program with RMAT/Fast Track designations, aligning with Alzheimer's disease therapeutics.
|
$12.51M |
$0.83
-0.57%
|
|
BTAI
BioXcel Therapeutics, Inc.
Targeting Alzheimer's disease agitation (AAD) expands into 'Alzheimer's Disease Therapeutics'.
|
$12.41M |
$2.07
+2.48%
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$7.33M |
$2.63
+0.96%
|
|
BIVI
BioVie Inc.
The pipeline includes Alzheimer's Disease Therapeutics, reflecting bezisterim's potential disease-modifying role in AD.
|
$3.25M |
$1.77
+0.28%
|
|
SILO
Silo Pharma, Inc.
Alzheimer's Disease Therapeutics aligns with SPC-14 program targeting Alzheimer's disease in Silo's pipeline.
|
$2.43M |
$0.55
-1.57%
|
Loading company comparison...
Loading industry trends...
Loading research report...
